Literature DB >> 32727754

Skeletal Muscle Mass Depletion After Gastrectomy Negatively Affects the Prognosis of Patients With Gastric Cancer.

Yoshikazu Kanazawa1, Takeshi Yamada2, Daisuke Kakinuma2, Kunihiko Matsuno2, Fumihiko Ando2, Itsuo Fujita2, Hitoshi Kanno2, Shunji Kato2, Hiroshi Yoshida2.   

Abstract

BACKGROUND/AIM: Skeletal muscle mass (SMM) is often depleted in patients with gastric cancer undergoing gastrectomy. Using a novel method, we evaluated the effect of SMM depletion after gastrectomy on disease prognosis. PATIENTS AND METHODS: The maximum cross-sectional area of the psoas-muscle (MCA-PM) was measured before surgery and at 1 year after in 233 patients with gastric cancer who underwent radical gastrectomy to determine the ratio (MCA-PMR) as an indicator of SMM depletion.
RESULTS: The MCA-PMR cutoff value was set at 90%, and patients were divided into the groups with <90% and ≥90%. MCA-PMR <90% was an independent prognostic factor for all patients. In 88 patients who received adjuvant chemotherapy including S-1, the 5-year cancer-specific survival rate was significantly better for those with MCA-PMR ≥90% than for those with MCA-PMR <90% (84.1% vs. 59.1%; p=0.010; hazard ratio=2.974; 95% confidence interval=1.241-7.124).
CONCLUSION: SMM depletion after gastrectomy can be measured using the MCA-PMR. This novel measurement can be easily implemented in the clinical setting. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Gastric cancer; gastrectomy; psoas muscle; survival rate

Mesh:

Year:  2020        PMID: 32727754     DOI: 10.21873/anticanres.14429

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Impact of loss of skeletal muscle mass within 6-12 months after gastrectomy and S1 adjuvant chemotherapy on the survival prognosis of elderly patients with gastric cancer.

Authors:  Shiro Fujihata; Shinichi Sakuramoto; Yosuke Morimoto; Kazuaki Matsui; Keiji Nishibeppu; Gen Ebara; Shohei Fujita; Shuichiro Oya; Hirofumi Sugita; Seigi Lee; Yutaka Miyawaki; Hiroshi Sato; Shuji Takiguchi; Keishi Yamashita
Journal:  Surg Today       Date:  2022-04-08       Impact factor: 2.540

2.  Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil.

Authors:  Tomoyuki Matsunaga; Hiroaki Saito; Wataru Miyauchi; Yuji Shishido; Kozo Miyatani; Masaki Morimoto; Yuki Murakami; Takehiko Hanaki; Kyoichi Kihara; Manabu Yamamoto; Naruo Tokuyasu; Shuichi Takano; Teruhisa Sakamoto; Toshimichi Hasegawa; Yoshiyuki Fujiwara
Journal:  BMC Cancer       Date:  2021-11-13       Impact factor: 4.430

3.  Combined systemic inflammatory immunity index and prognostic nutritional index scores as a screening marker for sarcopenia in patients with locally advanced gastric cancer.

Authors:  Ping'an Ding; Jingxia Lv; Chenyu Sun; Shuya Chen; Peigang Yang; Yuan Tian; Qin Zhou; Honghai Guo; Yang Liu; Qun Zhao
Journal:  Front Nutr       Date:  2022-08-15

4.  Impact of skeletal muscle mass in patients with recurrent gastric cancer.

Authors:  Tomoyuki Matsunaga; Hiroaki Satio; Wataru Miyauchi; Yuji Shishido; Kozo Miyatani; Yuki Murakami; Takehiko Hanaki; Kyoichi Kihara; Manabu Yamamoto; Naruo Tokuyasu; Shuichi Takano; Teruhisa Sakamoto; Toshimichi Hasegawa; Yoshiyuki Fujiwara
Journal:  World J Surg Oncol       Date:  2021-06-11       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.